{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:06:30Z","timestamp":1793423190365,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM135158"],"award-info":[{"award-number":["GM135158"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM067260"],"award-info":[{"award-number":["GM067260"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.kint.2020.03.030","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T05:03:23Z","timestamp":1592543003000},"page":"62-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel clinical manifestations and treatment of hereditary apoA-I amyloidosis: when a good protein turns bad"],"prefix":"10.1016","volume":"98","author":[{"given":"Olga","family":"Gursky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2020.03.030_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.kint.2020.03.030_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-3-319-17344-3_8","article-title":"Amyloid-forming properties of human apolipoproteins: sequence analyses and structural insights","volume":"855","author":"Das","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.kint.2020.03.030_bib3","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2020.03.030_bib4","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1038\/ncomms10353","article-title":"D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile","volume":"7","author":"Valleix","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2020.03.030_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.kint.2020.03.033","article-title":"New clinical forms of hereditary apoA-I amyloidosis entail both glomerular and retinal\u00a0amyloidosis","volume":"98","author":"Colombat","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.03.030_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jmb.2015.10.029","article-title":"Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A-I: what makes the protein amyloidogenic?","volume":"428","author":"Das","year":"2016","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.kint.2020.03.030_bib7","doi-asserted-by":"crossref","first-page":"129515","DOI":"10.1016\/j.bbagen.2020.129515","article-title":"Fibrillar conformation of an apolipoprotein A-I variant involved in amyloidosis and atherosclerosis","volume":"1864","author":"Gisonno","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.kint.2020.03.030_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MOL.0000000000000667","article-title":"Inborn errors of apolipoprotein A-I metabolism: implications for disease, research and development","volume":"31","author":"Zanoni","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.kint.2020.03.030_bib9","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1021\/acs.biochem.8b00817","article-title":"Molecular insights into human hereditary apolipoprotein A-I amyloidosis caused by the Glu34Lys mutation","volume":"57","author":"Morgado","year":"2018","journal-title":"Biochemistry"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820304130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820304130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:21:38Z","timestamp":1778664098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253820304130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0085253820304130"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2020.03.030","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel clinical manifestations and treatment of hereditary apoA-I amyloidosis: when a good protein turns bad","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.03.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}